Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Isofol Medical AB ( (SE:ISOFOL) ) is now available.
Isofol Medical AB announced an investor meeting to update stakeholders on the progress of their drug candidate, arfolitixorin, which is undergoing a phase Ib/II clinical study at Charité – Universitätsmedizin Berlin. This meeting, scheduled for November 13, 2025, will provide insights into the potential of arfolitixorin to address treatment gaps in cancer care, with opportunities for participants to engage in discussions both in-person and online.
More about Isofol Medical AB
Isofol Medical AB is a biotechnology company focused on enhancing cancer treatment efficacy. Their primary product, arfolitixorin, is a clinical-stage drug candidate aimed at improving the effectiveness of standard treatments for solid tumors, particularly colorectal cancer.
Average Trading Volume: 718,474
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK196.1M
See more data about ISOFOL stock on TipRanks’ Stock Analysis page.